A retrospective cohort study of prescription drug use among youth with intellectual/developmental disabilities in British Columbia

IF 2.1 2区医学 Q1 EDUCATION, SPECIAL

Journal of Intellectual Disability Research Pub Date : 2024-05-21 DOI:10.1111/jir.13147

S. Marquis, N. E. Marquis, Y. Lunsky, K. M. McGrail, J. Baumbusch

{"title":"A retrospective cohort study of prescription drug use among youth with intellectual/developmental disabilities in British Columbia","authors":"S. Marquis, N. E. Marquis, Y. Lunsky, K. M. McGrail, J. Baumbusch","doi":"10.1111/jir.13147","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>People with intellectual/developmental disabilities (IDD) are known to have high rates of prescription drug use, particularly for psychotropic medications. This is of concern due to the many side effects associated with these medications and because of the risks of polypharmacy. In this paper we compare the most commonly dispensed drugs and all psychotropic medications for youth with IDD compared with youth without IDD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using population-level administrative health data over a 10-year period, this study examined medications dispensed to youth with an IDD aged 15–24 years compared with youth without an IDD. The most common medications dispensed and the number of youth they were dispensed to were determined. As well a wide variety of psychotropic medications were examined.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were a total of 20 591 youth with IDD and 1 293 791 youth without IDD identified. Youth with IDD had higher odds of being dispensed pain medications, amoxicillin, salbutamol, levothyroxine and all the psychotropic medications (antidepressants, antipsychotics, anxiolytics, anti-adrenergic agents, mood stabilisers and stimulants). For youth with IDD, 6558 (31.85%) were dispensed two or more different psychotropic medications within a year, compared with 75 963 (5.87%) of youth without IDD.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>Compared to youth without IDD, youth with IDD had significantly higher odds of being dispensed most of the prescription medications studied, including all of the psychotropic medications. They were also twice as likely to be dispensed two or more medications from different classes of psychotropic drugs within the same year. These findings have important implications for the health of people with IDD and for their health care providers.</p>\n </section>\n </div>","PeriodicalId":16163,"journal":{"name":"Journal of Intellectual Disability Research","volume":"68 10","pages":"1156-1166"},"PeriodicalIF":2.1000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Intellectual Disability Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jir.13147","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"EDUCATION, SPECIAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

People with intellectual/developmental disabilities (IDD) are known to have high rates of prescription drug use, particularly for psychotropic medications. This is of concern due to the many side effects associated with these medications and because of the risks of polypharmacy. In this paper we compare the most commonly dispensed drugs and all psychotropic medications for youth with IDD compared with youth without IDD.

Methods

Using population-level administrative health data over a 10-year period, this study examined medications dispensed to youth with an IDD aged 15–24 years compared with youth without an IDD. The most common medications dispensed and the number of youth they were dispensed to were determined. As well a wide variety of psychotropic medications were examined.

Results

There were a total of 20 591 youth with IDD and 1 293 791 youth without IDD identified. Youth with IDD had higher odds of being dispensed pain medications, amoxicillin, salbutamol, levothyroxine and all the psychotropic medications (antidepressants, antipsychotics, anxiolytics, anti-adrenergic agents, mood stabilisers and stimulants). For youth with IDD, 6558 (31.85%) were dispensed two or more different psychotropic medications within a year, compared with 75 963 (5.87%) of youth without IDD.

Discussion

Compared to youth without IDD, youth with IDD had significantly higher odds of being dispensed most of the prescription medications studied, including all of the psychotropic medications. They were also twice as likely to be dispensed two or more medications from different classes of psychotropic drugs within the same year. These findings have important implications for the health of people with IDD and for their health care providers.

查看原文本刊更多论文

不列颠哥伦比亚省智力/发育障碍青少年处方药使用情况回顾性队列研究。

背景：众所周知，智力/发育障碍（IDD）患者的处方药使用率很高，尤其是精神药物。由于这些药物有很多副作用，而且存在多种用药的风险，因此这种情况令人担忧。在本文中，我们对患有 IDD 的青少年与未患有 IDD 的青少年最常使用的药物和所有精神药物进行了比较：本研究利用 10 年间的人口健康管理数据，对 15-24 岁患有 IDD 的青少年与未患有 IDD 的青少年的配药情况进行了比较。研究确定了最常见的配药及其配药人数。此外，还对各种精神药物进行了研究：共有 20 591 名患有 IDD 的青少年和 1 293 791 名未患有 IDD 的青少年被确认。患有 IDD 的青少年获得止痛药、阿莫西林、沙丁胺醇、左甲状腺素和所有精神药物（抗抑郁药、抗精神病药、抗焦虑药、抗肾上腺素能药、情绪稳定剂和兴奋剂）的几率更高。在患有 IDD 的青少年中，有 6558 人（31.85%）在一年内被配发了两种或两种以上不同的精神药物，而在没有 IDD 的青少年中，有 75963 人（5.87%）被配发了两种或两种以上不同的精神药物：讨论：与非智障青少年相比，智障青少年获得大部分处方药（包括所有精神药物）的几率明显更高。此外，他们在同一年内获得两种或两种以上不同类别精神药物的几率也要高出一倍。这些发现对 IDD 患者及其医疗服务提供者的健康具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Intellectual Disability Research Multiple-

CiteScore

5.60

自引率

5.60%

发文量

期刊介绍： The Journal of Intellectual Disability Research is devoted exclusively to the scientific study of intellectual disability and publishes papers reporting original observations in this field. The subject matter is broad and includes, but is not restricted to, findings from biological, educational, genetic, medical, psychiatric, psychological and sociological studies, and ethical, philosophical, and legal contributions that increase knowledge on the treatment and prevention of intellectual disability and of associated impairments and disabilities, and/or inform public policy and practice. Expert reviews on themes in which recent research has produced notable advances will be included. Such reviews will normally be by invitation.